Podcast Episodes
Back to Search
Markets Edition: AI – No Bubble, Yet
Scott T. Chronert, Head of U.S. Equity Strategy, and Drew Pettit of U.S. Equity Strategy discuss concerns about whether AI has led U.S. equities into…
5 months, 2 weeks ago
Episode 53: APEC at a Crossroad
Lucy Baldwin, Citi Head of Research, and Johanna Chua, Citi’s Global Head of Emerging Markets Economics, preview the APEC Summit by looking at the re…
5 months, 3 weeks ago
Markets Edition: The Debasement Trade
Dirk Willer, Citi’s Global Head of Macro Strategy and Asset Allocation, and Alex Saunders, Citi’s Head of Global Quant Macro Strategy, consider the d…
5 months, 3 weeks ago
Episode 52: Government Shutdown vs. the U.S. Economy
U.S. Regional Director of Research Rob Rowe and Veronica Clark, Senior U.S. Economist, discuss the U.S. government shutdown, how it may affect the U.…
5 months, 4 weeks ago
Markets Edition: Volatility is Back
Beata Manthey, Head of European Equity Strategy, and David Groman, Senior Global Equity Strategist, discuss why they see volatility in store for the …
6 months ago
Episode 51: Are US Consumers Still Consuming?
Are U.S. consumers still consuming? That's the central question at hand in our latest Research @ Citi podcast. North America Head of Research Anne Ma…
6 months ago
Markets Edition: The Bubble Playbook
In the latest Research @ Citi Markets Edition podcast, Citi’s Global Head of Macro Strategy Dirk Willer and Adam Pickett, Global Quant Macro Strategy…
6 months, 1 week ago
Episode 50: The Internet – Nothing's Going to be the Same
In the latest Research @ Citi podcast, North America Head of Equity Research Anne Malone sits down with Internet Analyst Ron Josey to discuss the pot…
6 months, 1 week ago
Markets Edition: The AI Impact on U.S. Equities
In the latest Research @ Citi Markets Edition podcast, Head of U.S. Equity Strategy Scott Chronert sits down with Drew Pettit, U.S. Equity Strategy, …
6 months, 2 weeks ago
Episode 49: Back to School on Biotech
Anne Malone, head of North America Equity Research, sits down with Geoff Meacham, U.S. pharma and biotech research analyst and head of healthcare res…
6 months, 2 weeks ago